

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A plant extract that inhibits the activity of at least one extracellular protease selected from the group of: matrix metalloprotease-1 (MMP-1), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9), and cathepsin B, said extract having at least one of the following properties:

- (i) is capable of slowing down or inhibiting migration of endothelial cells, and
- (ii) is capable of slowing down or inhibiting migration of neoplastic cells,
with the proviso that said extract is derived from a plant other than *Ginkgo biloba* or *Lupinus albus*.

2-24. (canceled)

25. (new) A plant extract that inhibits the activity of at least one extracellular protease selected from the group of: matrix metalloprotease-1 (MMP-1), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9), and cathepsin B, said extract having at least one of the following properties:

- (i) is capable of slowing down or inhibiting migration of endothelial cells, and
- (ii) is capable of slowing down or inhibiting migration of neoplastic cells,
wherein said extract is derived from a plant that has been subjected to one or more stress.

26. (new) The plant extract according to claim 25, wherein said stress is a chemical stress.

27. (new) The plant extract according to claim 1, wherein said extract is derived from any one of the plants listed in Table 1, 2, 3, 4 or 5.

28. (new) The plant extract according to claim 1, wherein said extract is derived from any one of the plants listed in Table 13 or 14.

29. (new) The plant extract according to claim 1, wherein said extract is selected from any one of the extracts listed in Table 13 or 14.

30. (new) The plant extract according to claim 1, wherein said extract is prepared by extraction using an alcoholic or aqueous solvent.

31. (new) A library of plant extracts capable of slowing down or inhibiting cell migration that are suitable for use in the preparation of pharmaceutical compositions for inhibition or prevention of angiogenesis and/or metastasis, said library being prepared by a process comprising:

- (a) selecting a group of plants;
- (b) harvesting plant material from each plant in said selected group of plants;
- (c) subjecting said plant material from each plant to three or more sequential extraction processes utilising different solvents to provide a plurality of potential extracts;
- (d) analysing each potential extract for inhibitory activity against at least one extracellular protease;
- (e) selecting those potential extracts that are capable of inhibiting the activity of at least one extracellular protease to provide a group of extracts;
- (f) analysing the ability of each extract in said group of extracts to slow down or inhibit migration of endothelial and/or neoplastic cells *in vitro*, and
- (g) selecting those extracts that are capable of slowing down or inhibiting migration of endothelial and/or neoplastic cells to provide said library of plant extracts.

32. (new) The library according to claim 31, wherein said process further comprises subjecting said selected group of plants to one or more stress prior to harvesting said plant material.

33. (new) The library according to claim 31, wherein said at least one extracellular protease is selected from the group of: matrix metalloprotease-1 (MMP-1), matrix

metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9), and cathepsin B.

34. (new) The library according to claim 31, wherein said library comprises plant extracts derived from the plants listed in any one of Tables 1, 2, 3, 4 or 5, or a combination thereof.

35. (new) A formulation comprising the plant extract according to claim 1 and a physiologically acceptable diluent, excipient or carrier.

36. (new) The plant extract according to claim 25, wherein said extract is derived from any one of the plants listed in Table 1, 2, 3, 4 or 5.

37. (new) The plant extract according to claim 25, wherein said extract is derived from any one of the plants listed in Table 13 or 14.

38. (new) The plant extract according to claim 25, wherein said extract is selected from any one of the extracts listed in Table 13 or 14.

39. (new) The plant extract according to claim 25, wherein said extract is prepared by extraction using an alcoholic or aqueous solvent.

40. (new) A formulation comprising the plant extract according to claim 25 and a physiologically acceptable diluent, excipient or carrier.

41. (new) The formulation according to claim 35, wherein said formulation slows down, inhibits or prevents angiogenesis.

42. (new) The formulation according to claim 40, wherein said formulation slows down, inhibits or prevents angiogenesis.

43. (new) The formulation according to claim 35, wherein said formulation slows down, inhibits or prevents metastasis.

44. (new) The formulation according to claim 35, wherein said formulation slows down, inhibits or prevents metastasis.